Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood reviews

• Publication date

  2017-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.blre.2017.03.002PMID 28336182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.

  2016cited by this paper
• CME Information: Immunoglobulin Light Chain Amyloidosis: 2016 Update on Diagnosis, Prognosis, and Treatment

  2016cited by this paper
• Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

  2016cited by this paper
• First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

  2016cited by this paper
• Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.

  2016cited by this paper
• Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.

  2016cited by this paper
• Guidelines on the diagnosis and investigation of AL amyloidosis

  2015cited by this paper
• Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis

  2015cited by this paper
• Renal Involvement in Monoclonal Gammopathy

  2015cited by this paper
• Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis

  2015cited by this paper
• Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

  2015cited by this paper
• Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

  2015cited by this paper
• Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

  2014cited by this paper
• Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans*

  2014cited by this paper
• Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity

  2014cited by this paper
• Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis

  2014cited by this paper
• A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.

  2014cited by this paper
• Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury

  2014cited by this paper
• Extrusion of Amyloid Fibrils to the Extracellular Space in Experimental Mesangial AL-Amyloidosis: Transmission and Scanning Electron Microscopy Studies and Correlation with Renal Biopsy Observations

  2014cited by this paper
• An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes.

  2014cited by this paper
• Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

  2014cited by this paper
• Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity

  2014cited by this paper
• Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes

  2013cited by this paper
• Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

  2013cited by this paper
• Extracellular chaperones and proteostasis.

  2013cited by this paper
• Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

  2013cited by this paper
• Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

  2013cited by this paper
• Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

  2012cited by this paper
• Ten‐year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

  2012cited by this paper
• Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.

  2012cited by this paper
• Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report

  2012cited by this paper
• The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

  2012cited by this paper
• Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains.

  2011cited by this paper
• The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.

  2011cited by this paper
• Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.

  2011cited by this paper
• Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance

  2011cited by this paper
• Clusterin facilitates in vivo clearance of extracellular misfolded proteins

  2011cited by this paper
• Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins.

  2011cited by this paper
• Disease-associated amyloid and misfolded protein aggregates activate the inflammasome.

  2011cited by this paper
• Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway

  2010cited by this paper
• Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

  2010cited by this paper
• The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.

  2010cited by this paper
• Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders

  2010cited by this paper
• Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and Fibrils*

  2010cited by this paper
• Dysregulation of miRNAs in AL amyloidosis

  2010cited by this paper
• Aggregates of denatured proteins stimulate nitric oxide and superoxide production in macrophages

  2010cited by this paper
• Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

  2010cited by this paper
• Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide.

  2010cited by this paper
• Immunophenotype of neoplastic plasma cells in AL amyloidosis

  2009cited by this paper
• Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

  2009cited by this paper
• Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis

  2009cited by this paper
• Fibril protein fragmentation pattern in systemic AL‐amyloidosis

  2009cited by this paper
• Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

  2008cited by this paper
• Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition

  2008cited by this paper
• Histomorphometric analysis of intramyocardial vessels in primary and senile amyloidosis: epicardium versus endocardium.

  2008cited by this paper
• Predictors of survival in patients with systemic light‐chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

  2008cited by this paper
• Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

  2008cited by this paper
• Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue*S

  2008cited by this paper
• Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade

  2008cited by this paper
• The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.

  2008cited by this paper
• apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

  2008cited by this paper
• Transplantation for amyloidosis

  2007cited by this paper
• Serum macroglobulin induces prion protein transition

  2007cited by this paper
• Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

  2007cited by this paper
• The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage.

  2007cited by this paper
• Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival.

  2007cited by this paper
• Increased plasmin‐α2‐antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses

  2007cited by this paper
• Role of translational research advancing the understanding of the pathogenesis of light chain‐mediated glomerulopathies

  2007cited by this paper
• The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer’s disease

  2007cited by this paper
• Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains.

  2007cited by this paper
• Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

  2007cited by this paper
• The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures

  2007cited by this paper
• High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

  2007cited by this paper
• Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

  2006cited by this paper
• Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.

  2006cited by this paper
• Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease

  2006cited by this paper
• Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage.

  2005cited by this paper
• β-Amyloid (Aβ) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation

  2005cited by this paper
• Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.

  2005cited by this paper
• Tissue plasminogen activator mediates amyloid‐induced neurotoxicity via Erk1/2 activation

  2005cited by this paper
• Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.

  2005cited by this paper
• Cellular response of cardiac fibroblasts to amyloidogenic light chains.

  2005cited by this paper
• Clinical aspects of systemic amyloid diseases.

  2005cited by this paper
• Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns

  2004cited by this paper
• AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells

  2004cited by this paper
• Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

  2004cited by this paper
• Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns

  2004cited by this paper
• Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress

  2004cited by this paper
• Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

  2003cited by this paper
• Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit

  2003cited by this paper
• Molecular mechanisms of amyloidosis.

  2003cited by this paper
• Insights into Mechanisms Responsible for Mesangial Alterations Associated with Fibrogenic Glomerulopathic Light Chains

  2003cited by this paper
• The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.

  2003cited by this paper
• The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration

  2003cited by this paper
• Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin.

  2002cited by this paper
• Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

  2002cited by this paper
• Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

  2002cited by this paper
• Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.

  2002cited by this paper
• Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment

  2002cited by this paper
• Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.

  2001cited by this paper

• 68Ga-FAPI-04 PET/CT for the Assessment of Light-Chain Cardiac Amyloidosis: A Promising Risk- Stratification Imaging Modality

  2025cites this paper
• In‐hospital outcomes among amyloidosis patients with atrial fibrillation: A propensity score‐matched analysis

  2024cites this paper
• Myocardial Mitochondrial Function Is Impaired in Cardiac Light-Chain Amyloidosis Compared to Transthyretin Amyloidosis.

  2024cites this paper
• Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.

  2024cites this paper
• Unfolding and Aggregation Pathways of Variable Domains from Immunoglobulin Light Chains.

  2023cites this paper
• Submandibular gland amyloidosis: A rare manifestation of extranodal marginal lymphoma – A case report and literature review

  2023cites this paper
• An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis

  2022cites this paper
• Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains

  2021cites this paper
• Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis

  2021cites this paper
• Semi-Quantification of Myocardial Uptake of Bone-Seeking Agents in Suspected Cardiac Amyloidosis

  2021cites this paper
• The AL Amyloid Fibril: Looking for a Link between Fibril Formation and Structure

  2021cites this paper
• 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

  2021cites this paper
• Amiloidosis cardiaca secundaria a macroglobulinemia de Waldenström

  2020cites this paper
• Current Updates on the Management of AL Amyloidosis

  2020cites this paper
• [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].

  2020cites this paper
• Cardiac amyloidosis — state-of-the-art diagnosis and emerging therapies

  2020cites this paper
• Abnormal serum carbohydrate antigen 19-9 levels in a patient with splenic retiform haemangioendothelioma concomitant with hepatic amyloidosis: A case report

  2020cites this paper
• Amyloid Proteins and Peripheral Neuropathy

  2020cites this paper
• 血清游离轻链检测在轻链型心肌淀粉样变性中的预后价值

  2020cites this paper
• MAGE genes: Prognostic indicators in AL amyloidosis patients

  2019cites this paper
• Multiorgan involvement by amyloid light chain amyloidosis

  2019cites this paper
• Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study

  2019cites this paper
• The Clinical Spectrum of Amyloidosis

  2018cites this paper
• Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

  2018cites this paper
• Localized conformational changes trigger the pH-induced fibrillogenesis of an amyloidogenic λ light chain protein.

  2018cites this paper
• Doksycyklina w terapii amyloidozy układowej z zajęciem serca

  2018cites this paper